Clinical Trials for Diabetes
126 diabetes trials indexed, 55 currently recruiting. Updated daily from ClinicalTrials.gov.
Understanding Diabetes
Diabetes is a chronic health condition that affects how the body processes blood sugar, also called glucose. Normally, the hormone insulin helps glucose enter cells to be used for energy. In diabetes, the body either does not produce enough insulin or cannot use it properly. This leads to high levels of glucose in the blood, which can cause damage over time. Doctors diagnose diabetes through blood tests that measure glucose levels, such as the fasting plasma glucose test or the A1C test, which reflects average blood sugar over several months.
Common symptoms of diabetes include increased thirst, frequent urination, fatigue, and blurred vision. Type 1 diabetes often begins in childhood or adolescence, while type 2 diabetes usually develops in adults but is increasingly seen in younger people. Those most affected include people with a family history of diabetes, individuals who are overweight or inactive, and certain ethnic groups like African Americans, Hispanics, and Native Americans. Risk factors also include high blood pressure, unhealthy diet, and age over 45 years.
Diabetes is a major medical and social concern worldwide. According to the Centers for Disease Control and Prevention (CDC), over 37 million people in the United States have diabetes, which is about 11% of the population. It contributes to serious complications such as heart disease, kidney failure, and vision loss. The condition also places a heavy economic burden on healthcare systems, with estimated costs exceeding $300 billion annually in the U.S. alone. Managing diabetes effectively is important to reduce these risks and improve quality of life.
The Diabetes Treatment Landscape
The first-line treatment for type 2 diabetes typically includes lifestyle changes such as improved diet, increased physical activity, and weight loss. When lifestyle adjustments are not enough, doctors often prescribe metformin as the initial medication. Metformin helps lower glucose production in the liver and improves insulin sensitivity. Treatment usually starts with one drug, and doses are adjusted based on blood sugar control. Regular monitoring guides whether additional therapies are needed to maintain target glucose levels.
Second- and third-line treatment options include several drug classes. Sulfonylureas increase insulin release from the pancreas. DPP-4 inhibitors help prolong the action of hormones that stimulate insulin secretion. GLP-1 receptor agonists mimic natural hormones to enhance insulin release and reduce appetite. SGLT2 inhibitors work by causing the kidneys to remove excess glucose through urine. Insulin therapy may be introduced when oral medications no longer provide adequate control. These options provide various ways to manage diabetes but may have different side effects and benefits.
Despite many available treatments, gaps remain in managing diabetes effectively. Some patients do not respond well to standard therapies or develop resistance. Side effects such as low blood sugar, weight gain, or gastrointestinal issues can limit medication use. Certain subgroups, including older adults and those with multiple health problems, may face particular challenges. Research is ongoing to find better treatments with fewer side effects and to address complications like diabetic neuropathy and cardiovascular risk. Clinical trials continue to explore new approaches to improve outcomes for all patients.
Why Clinical Trials Matter for Diabetes
Participating in clinical trials offers patients access to new treatments that are not yet widely available. These studies also provide closer medical monitoring and support throughout the trial period. By joining a clinical trial, patients contribute to advancing scientific knowledge that may benefit future generations. Currently, ClinicalTrials.gov lists 126 diabetes clinical trials, with 55 actively recruiting participants. This shows ongoing efforts to develop and test better therapies for this common condition.
However, clinical trials come with certain risks. The effectiveness of new treatments is not guaranteed, and some participants may receive a placebo instead of the active drug. Additional clinic visits and tests are often required, which may be inconvenient. Side effects from experimental treatments can occur and may be unknown at the start of the trial. It is important for patients to discuss these factors with their healthcare providers before deciding to join a study.
The landscape of diabetes clinical trials includes sponsors from various sectors. Academic institutions often conduct investigator-initiated studies focused on understanding disease mechanisms. Pharmaceutical companies develop new medications and devices through industry-sponsored trials. Cooperative groups may organize large multi-center studies to test treatments across diverse populations. ClinicalTrials.gov serves as a central registry that tracks these studies, providing transparency and helping patients find trials that match their needs.
What to Look for in a Diabetes Clinical Trial
Clinical trials are divided into four main phases that test new treatments for safety and effectiveness. Phase 1 trials focus on safety and dosage with a small group of participants. Phase 2 trials study the treatment’s effectiveness and side effects in a larger group. Phase 3 trials compare the new treatment to standard care in an even larger population. Phase 4 trials happen after approval to monitor long-term effects. For diabetes trials, many studies do not specify a phase, with 52 listed as NA. Phase 2 trials are most common, with 14 studies, followed by 9 in Phase 1 and 5 in Phase 3.
When joining a diabetes clinical trial, you will need to meet certain inclusion criteria. These often include specific age ranges, such as adults over 18 or sometimes older adults only. Trials may require participants to have a particular type of diabetes, like type 1 or type 2. Some studies ask for certain biomarkers, such as blood sugar levels or HbA1c within a set range. The duration of diabetes or prior treatments, like insulin use or oral medications, can also affect eligibility. These criteria help ensure the study results apply to the right patient group.
Exclusion criteria are just as important. They prevent people with conditions that could interfere with the study or increase risk from participating. Common exclusions include other serious illnesses like heart or kidney disease. Some trials exclude participants taking certain medications that might interact with the study drug. Safety thresholds, such as kidney function or liver enzyme levels, are used to protect participants. These rules help keep the trial results accurate and participants safe.
Practical factors matter when deciding to join a trial. Consider how long the study lasts and how often you must visit the clinic. Frequent visits or long travel distances can be challenging. Ask the research team about the total time commitment and if travel costs are covered. Four important questions to ask are: What are the possible benefits and risks? How will the treatment affect my current medications? What happens if I experience side effects? Can I leave the trial at any time? These questions help you make an informed choice about participation.
Primary Sources and Further Reading
For those interested in learning more about diabetes clinical trials and related information, it is important to consult trusted sources. These websites provide reliable, up-to-date details on diabetes research, treatment options, and clinical trial opportunities. They also offer guidance on managing diabetes and understanding the science behind new therapies.
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) - Diabetes
- ClinicalTrials.gov - Diabetes Trials
- MedlinePlus - Diabetes
- Centers for Disease Control and Prevention (CDC) - Diabetes
- National Institutes of Health (NIH) - NIDDK Overview
Latest Research and Emerging Treatments for Diabetes (2026)
New diabetes treatments are being studied to help people with type 1 diabetes manage their condition better. One promising option is Diamyd, an immunotherapy injection tested in adolescents and adults newly diagnosed with type 1 diabetes (NCT05018585). Diamyd contains a protein called recombinant human glutamic acid decarboxylase (rhGAD65), which may help preserve the body's ability to produce insulin naturally. Preserving insulin production could improve blood sugar control and reduce the dependence on insulin injections for some patients.
Other research is exploring drugs like dimethyl fumarate, which is being tested for its potential to protect insulin-producing cells in adults with new type 1 diabetes (NCT07258394). This drug is taken as a capsule and may help reduce the immune system's attack on these cells. Similarly, teplizumab is another drug under study for young people aged 1 to 25 years with newly diagnosed type 1 diabetes (NCT07088068). It works by modifying the immune response to slow down the loss of insulin-producing cells. These new drugs for diabetes focus on preserving the body's own insulin production, which could improve quality of life and reduce the burden of daily insulin injections.
For patients who have had a kidney transplant, VX-880 is being tested as a biological treatment to see if it can restore insulin production and reduce the need for insulin shots (NCT06832410). Additionally, islet transplantation using the UIC protocol is another approach studied to improve blood sugar control by transplanting insulin-producing cells (NCT00679042). These diabetes new treatments in 2026 reflect ongoing diabetes research aimed at offering more options beyond traditional insulin therapy. If successful, these treatments could change how people live with type 1 diabetes by improving blood sugar control and reducing complications.
Frequently asked questions about Diabetes trials
How do I find Diabetes clinical trials?
The authoritative source for Diabetes clinical trials is ClinicalTrials.gov, maintained by the U.S. National Library of Medicine. 126 diabetes studies are currently indexed. You can search by entering "diabetes" as the condition, then filter by recruiting status, phase, and location. TrialsAlert scans ClinicalTrials.gov daily for new diabetes trials and delivers a plain-language briefing every Friday explaining what changed.
What phase are most Diabetes trials in?
Across the 126 diabetes trials TrialsAlert indexes, the most common phase is Phase 2. Early-phase studies (Phase 1 and Phase 2) test safety and initial efficacy. Phase 3 trials compare a candidate treatment against the current standard of care in larger populations and generate the evidence regulators use to approve new therapies.
How many Diabetes clinical trials are currently recruiting?
As of the latest scan, 55 diabetes trials have a "Recruiting" status on ClinicalTrials.gov, out of 126 total indexed. The recruiting figure changes daily as studies open, fill enrollment, and close. TrialsAlert subscribers are notified when a new recruiting diabetes trial matches their tracked condition.
Stay informed about diabetes research
Get a weekly briefing with the trials that matter most.